{
    "id": "b8c1c31e-710f-4828-98ea-51f0a7818d43",
    "indications": "Tydemy is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: Prevent pregnancy. ( 1.1 ) Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 )",
    "contraindications": "Take one tablet daily by mouth at the same time every day. ( 2.1 ) Tablets must be taken in the order directed on the blister pack. ( 2.1 )",
    "warningsAndPrecautions": "Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets) is available in blister pack containing 28 tablets packed in a pouch (NDC 68180-904-71). Such three pouches are packaged in a carton (NDC 68180-904-73). \n                        Each blister contains 28 film-coated tablets in the following order: \n                        \n                           21 orange, round shaped, biconvex film-coated tablets debossed with \"LU\" on one side and \"J63\" on other side each containing 3 mg drospirenone, 0.03 mg ethinyl estradiol and 0.451 mg levomefolate calcium.\n                           7 light orange, round shaped, biconvex film-coated tablets debossed with \"LU\" on one side and \"J62\" on other side each containing 0.451 mg levomefolate calcium.",
    "adverseReactions": "Tydemy is contraindicated in females who are known to have or develop the following conditions: \n                  \n                     Renal impairment\n                     Adrenal      insufficiency\n                     A high risk of arterial or      venous thrombotic diseases. Examples include women who are known to:\n                           Smoke,      if over age 35 [see Boxed Warning and Warnings and Precautions (5.1)] \n                           \n                           Have deep vein thrombosis or      pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)] \n                           \n                           Have cerebrovascular disease [see      Warnings and Precautions (5.1)] \n                           \n                           Have coronary artery disease [see Warnings and Precautions (5.1)] \n                           \n                           Have      thrombogenic valvular or thrombogenic rhythm diseases of the heart (for      example, subacute bacterial endocarditis with valvular disease, or atrial      fibrillation) [see Warnings and Precautions (5.1)] \n                           \n                           Have inherited or acquired      hypercoagulopathies [see Warnings and Precautions (5.1)]\n                           \n                           Have      uncontrolled hypertension [see Warnings and Precautions (5.6)] \n                           \n                           Have diabetes mellitus with      vascular disease [see Warnings and Precautions (5.8)] \n                           \n                           Have headaches with focal      neurological symptoms or have migraine headaches with or without aura if over age 35 [see Warnings      and Precautions (5.9)] \n                           \n                        \n                     \n                     Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.10)]\n                     \n                     Current diagnosis of, or      history of, breast cancer, which may be hormone-sensitive [see      Warnings and Precautions (5.3)] \n                     \n                     Liver tumor (benign or malignant) or liver disease [see Warnings and      Precautions (5.4) and Use in Specific Populations      (8.7)] \n                     \n                     Use of Hepatitis C drug combinations containing      ombitasvir/paritaprevir/ritonavir, with or without dasabuvir due to the      potential for ALT elevations [see Warnings and Precautions (5.5)      and Drug Interactions (7.3)].",
    "ingredients": [],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "Tydemy",
    "effectiveTime": "20250505"
}